Martin Freed - Dicerna Pharmaceuticals Independent Director
Director
Dr. Martin Freed, M.D. is Independent Director of the Company. Dr. Freed has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015. He cofounded and served as chief medical officer of Civitas Therapeutics, Inc., from December 2010 to October 2014, and as senior vice president, clinical development of Acorda from October 2014 through January 2015. In addition, Dr. Freed has served as chief medical officer and has provided strategic and operational planning and execution, as well as medical leadership for clinical pharmacology and development strategy and preclinical development for multiple pharmaceutical companies throughout his career. These companies include Avila Therapeutics, Inc., Taligen Therapeutics, Adnexus Therapeutics, Inc., and Vitae Pharmaceuticals, Inc. Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals or SmithKline Beecham, where he served numerous roles including vice president, clinical development and medical affairs in the metabolism therapeutic area. Dr. Freed currently serves as an independent director for Sojournix, Inc., and previously served as an independent director of InteKrin Therapeutics Inc. from 2007 to 2010. He has authored over 100 publications or presentations since 2016.
| Age | 57 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 617 621-8097 |
| Web | www.dicerna.com |
Dicerna Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (10.43) % which means that it has lost $10.43 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (95.22) %, meaning that it created substantial loss on money invested by shareholders. Dicerna Pharmaceuticals' management efficiency ratios could be used to measure how well Dicerna Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 64.42 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Dicerna Pharmaceuticals has a current ratio of 2.41, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dicerna Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Dicerna Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dicerna Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dicerna to invest in growth at high rates of return. When we think about Dicerna Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jeffrey Miller | ServiceNow | 68 | |
| Steven Wunning | Summit Materials | 70 | |
| Guy Jackson | Digi International | 72 | |
| Ronald Codd | ServiceNow | 61 | |
| Joseph Cantie | Summit Materials | 57 | |
| Richard Hill | Arrow Electronics | 69 | |
| Dale Friend | Flexible Solutions Internationa | 59 | |
| Herbert Parker | Apogee Enterprises | 60 | |
| Frederic Luddy | ServiceNow | 69 | |
| Ursula Burns | Uber Technologies | 62 | |
| Fabian Garcia | Arrow Electronics | 61 | |
| Garrett Camp | Uber Technologies | 44 | |
| Satbir Khanuja | Digi International | 50 | |
| Ben Seaman | Flexible Solutions Internationa | 38 | |
| Susan Ellerbusch | Summit Materials | 53 | |
| Anne Wade | Summit Materials | 48 | |
| John Thain | Uber Technologies | 65 | |
| Julia Kahr | Summit Materials | 37 | |
| Robert Helina | Flexible Solutions Internationa | 53 | |
| Amanda Ginsberg | Uber Technologies | 51 | |
| John Bientjes | Flexible Solutions Internationa | 66 | |
Management Performance
| Return On Equity | -95.22 | |||
| Return On Asset | -10.43 |
Dicerna Pharmaceuticals Leadership Team
Elected by the shareholders, the Dicerna Pharmaceuticals' board of directors comprises two types of representatives: Dicerna Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dicerna. The board's role is to monitor Dicerna Pharmaceuticals' management team and ensure that shareholders' interests are well served. Dicerna Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dicerna Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bruce Peacock, Independent Director | ||
| Dennis Langer, Independent Director | ||
| David Madden, Independent Chairman of the Board | ||
| Steven Kates, Vice President - Regulatory Affairs | ||
| Douglas Fambrough, President CEO, Director | ||
| Theodore Ashburn, Senior Vice President - Product Strategy & Operations | ||
| Martin Freed, Independent Director | ||
| Kevin Buchi, Independent Director | ||
| Peter Kolchinsky, Independent Director | ||
| Bob Brown, Chief Scientific Officer and Sr. VP | ||
| Brian Halak, Independent Director | ||
| Adam Koppel, Independent Director | ||
| Ralf Rosskamp, Chief Medical Officer | ||
| Rob Ciappenelli, Chief Commercial Officer | ||
| Marc Kozin, Director | ||
| James Weissman, Chief Bus. Officer | ||
| Hardean Achneck, Vice President Head of Medical Development | ||
| John Green, Interim CFO | ||
| Rebecca Peterson, Head of Corporate Communications | ||
| Stephen Hoffman, Independent Director | ||
| Anna Protopapas, Director | ||
| Cynthia Smith, Independent Director | ||
| Robert Ciappenelli, Chief Commercial Officer | ||
| David Caponera, Head of Patient Advocacy and Patient Services | ||
| Regina Paglia, Senior Vice President of Human Resources | ||
| Pankaj Bhargava, Chief Medical Officer |
Dicerna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dicerna Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -95.22 | |||
| Return On Asset | -10.43 | |||
| Profit Margin | (64.53) % | |||
| Operating Margin | (62.88) % | |||
| Current Valuation | 2.48 B | |||
| Shares Outstanding | 77.91 M | |||
| Shares Owned By Insiders | 7.43 % | |||
| Shares Owned By Institutions | 88.54 % | |||
| Number Of Shares Shorted | 4.77 M | |||
| Price To Earning | (1.58) X |
Pair Trading with Dicerna Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dicerna Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dicerna Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Nextera Energy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nextera Energy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nextera Energy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nextera Energy to buy it.
The correlation of Nextera Energy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nextera Energy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nextera Energy moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nextera Energy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Dicerna Stock
If you are still planning to invest in Dicerna Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dicerna Pharmaceuticals' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |